Get to know our clinical trials
Clinical trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a tri-specific T-lymphocyte enhancer from Humabody®, in patients with advanced and/or metastatic PSMA-positive solid tumors (POTENTIA).
THE AIM OF THE STUDY IS TO EVALUATE THE SAFETY, TOLERABILITY AND OPTIMAL DOSE OF THE STUDY DRUG, CB307.
Status
In recruitment
headquarters
Multisede
Technical Summary
- PHASE 1 OPEN-LABEL DOSE-ESCALATION AND EXPANSION TRIAL TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF CB307, A TRI-SPECIFIC T-LYMPHOCYTE ENHANCER FROM HUMABODY®, IN PATIENTS WITH ADVANCED AND/OR METASTATIC PSMA-POSITIVE SOLID TUMORS (POTENTIA). IMMUNOTHERAPY
- Code EudraCT: 2019-004584-46
- Protocol number: CBT307-1
- Promoter: Crescendo Biologics Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.